Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis

Abstract EN

Background.

Immunosuppression is a well-recognised complication of chemotherapy in cancer patients.

We assemble the clinical evidence that SQI, an adjuvant drug for lung cancer and gastric cancer which was widely prescribed in China, interventions could increase objective tumour response and regulate immunity in cancer patients undergoing chemotherapy.

Methods.

We undertook a systemic review of the clinical data from randomised controlled trials up to September 2015 in which a SQI intervention was compared with a control arm in patients undergoing conventional chemotherapy.

Revman 5.0 Software was used for the data analysis.

Results.

49 randomised controlled trials were included in the systematic review.

The meta-analysis results demonstrated that the SQI intervention with conventional chemotherapy exhibited better therapeutic efficacy than the conventional chemotherapy group with a statistically significant higher objective tumour response.

Cotreatment with SQI could enhance NK, CD3+, CD4+ level, and CD4+/CD8+ ratio comparing with the conventional chemotherapy group.

Conclusions.

The conclusions of this review might suggest a high risk of bias due to the low quality and the limitation of cancer types in the included trials.

A more reliable conclusion regarding the immunoregulation of SQI could be reached based on more trials of higher quality.